Anadys Pharmaceuticals, Inc. (ANDS) Reports Third Quarter 2009 Financial Results and Program Highlights
10/30/2009 10:40:41 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) to Report Third Quarter 2009 Financial Results
10/23/2009 9:15:04 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) to Present at Two Upcoming Investor Conferences
10/21/2009 8:40:20 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) to present at the JMP Securities Healthcare Focus Conference
9/29/2009 9:23:12 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) Commences Dosing in Phase II Study of ANA598
9/9/2009 10:43:28 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) Moves Hepatitis C Drug Ahead on its Own, Intellikine, Inc. (JOBS) Casts a Broad Net, Sequel Pharmaceuticals Raising $8.4 Million
8/20/2009 7:16:04 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS)'s ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients Proof of Concept Achieved for Second Anadys HCV Product Candidate
8/11/2009 9:10:23 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) Reports Second Quarter 2009 Financial Results and Program Highlights
7/31/2009 9:36:37 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
7/31/2009 8:53:42 AM
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) to Report Second Quarter 2009 Financial Results
7/24/2009 8:40:52 AM
More...
|
|